News Daily News Most Supplements and Diets Don’t Lower CVD or Mortality Risks Michael O'Riordan July 09, 2019
News Daily News High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk Michael O'Riordan July 01, 2019
News Conference News EAS 2019 CHD Mortality Significantly Elevated in Patients With Severe FH Michael O'Riordan May 29, 2019
News Conference News HRS 2019 Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib Todd Neale May 17, 2019
News Daily News Familial Hypercholesterolemia Seen in 10% of Young MI Patients Michael O'Riordan May 15, 2019
News Daily News No Need for Niacin? Meta-analysis Argues the End Is Nigh Yael L. Maxwell April 22, 2019
News Conference News ACC 2019 REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events Yael L. Maxwell March 22, 2019
News Daily News Rising Number of CV-Related Maternal Deaths Spurs Need for #CardioObstetrics Caitlin E. Cox February 27, 2019
News Daily News Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests Todd Neale February 01, 2019
News Daily News Flu Tied to Worse Outcomes in Patients Hospitalized With Heart Failure Todd Neale January 03, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2018 Caitlin E. Cox January 01, 2019
News Conference News WCC 2018 CVD, Other Noncommunicable Diseases Hit Lower-Income Countries With Heavy Financial Burden Todd Neale December 06, 2018
News Daily News Certain Risk Factors Carry Higher MI Risk in Women Than in Men Shelley Wood November 23, 2018
News Daily News Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts Michael O'Riordan November 23, 2018
News Conference News AHA 2018 EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits Michael O'Riordan November 16, 2018
News Opinion Conversations in Cardiology Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC? November 16, 2018
News Conference News AHA 2018 Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study Michael O'Riordan November 15, 2018
News Conference News VIVA 2018 Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease L.A. McKeown November 15, 2018
News Conference News AHA 2018 Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis Caitlin E. Cox November 13, 2018